High-titer foamy virus vector transduction and integration sites of human CD34+ cell-derived SCID-repopulating cells

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14020-

  Nasimuzzaman, Md ^a   Kim, Yoon Sang ^a   Wang, Yong Dong ^a   Persons, Derek A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934448204     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.20     Document Type: Article

References (38)

1. Linial, ML (2007). Foamy viruses. In: Fields, BNK, Howley, DM, Peter, M. (eds.). Fields Virology, vol. 1. Lippincott Williams & Wilkins: Philadelphia. pp. 2245-2262.
2. Trobridge, GD, Miller, DG, Jacobs, MA, Allen, JM, Kiem, H P, Kaul, R et al. (2006). Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 103: 1498-1503.
3. Bauer, TR Jr, Allen, JM, Hai, M, Tuschong, LM, Khan, IF, Olson, EM et al. (2008). Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 14: 93-97.
4. Saïb, A, Puvion-Dutilleul, F, Schmid, M, Périès, J and de Thé, H (1997). Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 71: 1155-1161.
5. Trobridge, G and Russell, DW (2004). Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 78: 2327-2335.
6. Trobridge, G, Josephson, N, Vassilopoulos, G, Mac, J and Russell, DW (2002). Improved foamy virus vectors with minimal viral sequences. Mol Ther 6: 321-328.
7. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
8. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
9. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
10. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, M P, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
11. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
12. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467: 318-322.
13. Kiem, H P, Allen, J, Trobridge, G, Olson, E, Keyser, K, Peterson, L et al. (2007). Foamy-virus-mediated gene transfer to canine repopulating cells. Blood 109: 65-70.
14. Josephson, NC, Trobridge, G and Russell, DW (2004). Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors. Hum Gene Ther 15: 87-92.
15. Hacein-Bey-Abina, S, Garrigue, A, Wang, G P, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
16. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
17. Schmidt, M, Schwarzwaelder, K, Bartholomae, C, Zaoui, K, Ball, C, Pilz, I et al. (2007). High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 4: 1051-1057.
18. Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J et al. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232.
19. Schwarzwaelder, K, Howe, SJ, Schmidt, M, Brugman, MH, Deichmann, A, Glimm, H et al. (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117: 2241-2249.
20. Patton, GS, Erlwein, O and McClure, MO (2004). Cell-cycle dependence of foamy virus vectors. J Gen Virol 85(Pt 10): 2925-2930.
21. Hanawa, H, Kelly, PF, Nathwani, AC, Persons, DA, Vandergriff, JA, Hargrove, P et al. (2002). Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5: 242-251.
22. Boussif, O, Lezoualc'h, F, Zanta, MA, Mergny, MD, Scherman, D, Demeneix, B et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301.
23. Josephson, NC, Vassilopoulos, G, Trobridge, GD, Priestley, GV, Wood, BL, Papayannopoulou, T et al. (2002). Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 99: 8295-8300.
24. Larochelle, A, Vormoor, J, Hanenberg, H, Wang, JC, Bhatia, M, Lapidot, T et al. (1996). Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 2: 1329-1337.
25. Gardiner-Garden, M and Frommer, M (1987). CpG islands in vertebrate genomes. J Mol Biol 196: 261-282.
26. Akinc, A, Thomas, M, Klibanov, AM and Langer, R (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7: 657-663.
27. Williams, DA (2000). Stem cell model of hematopoiesis. In: Hoffman, R, Benz, EJ, Shattil, SJ, et al. (ed). Hematology: Basic Principles and Practice. Churchill Livingstone: London, UK. pp. 126-138.
28. Miller, DG, Adam, MA and Miller, AD (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239-4242.
29. Takatoku, M, Sellers, S, Agricola, BA, Metzger, ME, Kato, I, Donahue, RE et al. (2001). Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. J Clin Invest 108: 447-455.
30. Glimm, H, Oh, IH and Eaves, CJ (2000). Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 96: 4185-4193.
31. Burns, JC, Friedmann, T, Driever, W, Burrascano, M and Yee, JK (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90: 8033-8037.
32. Wu, C, Jares, A, Winkler, T, Xie, J, Metais, JY and Dunbar, CE (2013). High efficiency restriction enzyme-free linear amplification-mediated polymerase chain reaction approach for tracking lentiviral integration sites does not abrogate retrieval bias. Hum Gene Ther 24: 38-47.
33. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
34. Ohmine, K, Li, Y, Bauer, TR Jr, Hickstein, DD and Russell, DW (2011). Tracking of specific integrant clones in dogs treated with foamy virus vectors. Hum Gene Ther 22: 217-224.
35. Schröder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
36. Uchiyama, T, Adriani, M, Jagadeesh, GJ, Paine, A and Candotti, F (2012). Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome. Mol Ther 20: 1270-1279.
37. Kingston, RE, Chen, CA and Rose, JK (2003). Calcium phosphate transfection. Curr Protoc Mol Biol Chapter 9: Unit 9.1.
38. Nasimuzzaman, M and Persons, DA (2012). Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther 20: 1158-1166.